Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers ComebackSeeking Alpha • 04/29/25
Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's WegovyInvestors Business Daily • 04/29/25
Hims & Hers Health (HIMS) stock surges 34% on partnership with Novo Nordisk to sell WegovyInvezz • 04/29/25
Hims & Hers Stock Soars 45%. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters.Barrons • 04/29/25
Novo Nordisk (NVO) Outperforms Broader Market: What You Need to KnowZacks Investment Research • 04/28/25
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, OzempicCNBC • 04/25/25
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?Zacks Investment Research • 04/24/25
Novo Nordisk Pops After Leapfrogging Eli Lilly With An Obesity PillInvestors Business Daily • 04/22/25
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.The Motley Fool • 04/22/25